Calquence and Daclizumab Subcutaneous

• Generic Name: acalabrutinib
• Dosage Forms: capsule, gelatin coated
• Other Brand Names: Calquence

Calquence (acalabrutinib) blocks the action of certain enzymes in the body, which can interfere with the growth and spread of cancer cells.

Calquence is used to treat mantle cell lymphoma (a type of non-Hodgkin lymphoma) in adults. This medicine is given after other treatments have failed.

Calquence was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, patients responded to this medicine. However, further studies are needed.

Calquence is also used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults.

• Generic Name: daclizumab
• Dosage Forms: n.a.
• Other Brand Names: Zinbryta, Zenapax

Daclizumab injection is used to treat the relapsing forms of multiple sclerosis (MS). Daclizumab will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. It should only be used when other medicines to treat MS did not work well.

Daclizumab was available only under a restricted distribution program called the Zinbryta® REMS (Risk Evaluation and Mitigation Strategy) Program.

Daclizumab was voluntarily withdrawn from the worldwide market on March 2, 2018 due to safety concerns.